Global pharmaceutical company Lupin Limited has been included for the first time in the Dow Jones Best-in-Class Indices 2026, marking a significant milestone in the company’s environmental, social, and governance (ESG) journey. The Mumbai-headquartered drugmaker has secured a place in both the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class Emerging Markets Index, reflecting its strong performance in sustainability and responsible business practices.
The recognition highlights Lupin’s continued focus on ethical governance, environmental stewardship, social responsibility, and long-term value creation. The Dow Jones Best-in-Class Indices, formerly known as the Dow Jones Sustainability Indices (DJSI), are regarded among the most respected global benchmarks for corporate sustainability performance.
The Dow Jones Best-in-Class World Index tracks the top-performing companies globally on sustainability parameters, while the Emerging Markets Index recognizes leading companies from developing economies based on ESG excellence. Companies included in these indices are selected through the S&P Global Corporate Sustainability Assessment (CSA), one of the world’s most comprehensive evaluations of corporate sustainability practices.
Lupin’s inclusion follows its strong showing in the S&P Global CSA 2025, where the company achieved an industry-leading score of 91 out of 100 and ranked among the top 1% of companies globally in its sector. The assessment evaluated performance across multiple parameters, including governance, operational efficiency, climate strategy, supply chain practices, employee engagement, healthcare accessibility, and ethical business conduct.
Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU at Lupin, said the recognition reflects the company’s long-term commitment to responsible growth and operational excellence.
“Lupin’s inclusion in the Dow Jones Best-in-Class Indices reflects the strength of our governance framework and financial discipline and marks a meaningful advancement in our sustainability journey. This recognition reinforces our long-term value creation agenda—anchored in responsible growth, resilient performance, and our continued commitment to delivering affordable, high-quality medicines to patients worldwide,” he said.
Lupin continues to advance its sustainability roadmap through science-based environmental targets, responsible sourcing initiatives, workplace inclusion, and high standards of quality and safety across operations. The company is also focused on improving healthcare access and strengthening patient outcomes through innovation and digital healthcare initiatives.
Headquartered in Mumbai, Lupin operates in more than 100 markets worldwide and maintains a strong presence in India and the United States. Its portfolio includes branded and generic formulations, biotechnology products, complex generics, and active pharmaceutical ingredients across therapeutic areas such as respiratory care, cardiovascular health, diabetes, gastrointestinal disorders, anti-infectives, central nervous system therapies, and women’s health.
